These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 34536028)

  • 1. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
    Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
    J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers.
    Suwarti S; Lazarus G; Zanjabila S; Sinto R; Fransiska F; Deborah T; Oktavia D; Junaidah J; Santayana S; Surendra H; Yuliana J; Pardosi H; Nuraeni N; Soebianto S; Susilowati ND; Subekti D; Pradipta A; Baird JK; Tan LV; Dunachie S; Shankar AH; Nelwan EJ; Hamers RL;
    BMC Infect Dis; 2024 Aug; 24(1):768. PubMed ID: 39090537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
    J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Ebinger JE; Fert-Bober J; Printsev I; Wu M; Sun N; Prostko JC; Frias EC; Stewart JL; Van Eyk JE; Braun JG; Cheng S; Sobhani K
    Nat Med; 2021 Jun; 27(6):981-984. PubMed ID: 33795870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2024 Jul; 42(19):3999-4010. PubMed ID: 38744598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2.
    Cohen CA; Leung NHL; Kaewpreedee P; Lee KWK; Jia JZ; Cheung AWL; Cheng SMS; Mori M; Ip DKM; Poon LLM; Peiris JSM; Cowling BJ; Valkenburg SA
    Nat Commun; 2024 Aug; 15(1):7358. PubMed ID: 39191745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
    Gabitzsch E; Safrit JT; Verma M; Rice A; Sieling P; Zakin L; Shin A; Morimoto B; Adisetiyo H; Wong R; Bezawada A; Dinkins K; Balint J; Peykov V; Garban H; Liu P; Bacon A; Bone P; Drew J; Sanford DC; Spilman P; Sender L; Rabizadeh S; Niazi K; Soon-Shiong P
    Front Immunol; 2021; 12():729837. PubMed ID: 34603305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest Russian vaccine comes with a big dose of mystery.
    Dobrovidova O
    Science; 2021 Apr; 372(6538):116-117. PubMed ID: 33833104
    [No Abstract]   [Full Text] [Related]  

  • 18. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.